The Avian Influenza Virus (H5N1): A Literature Review

Topical finasteride in Europe is often seen as less effective than oral forms, with users suggesting alternative application methods for better results. Many prefer oral finasteride due to cost and effectiveness.

The user experienced thicker hair and less hair loss after using topical finasteride (0.5%) and minoxidil (5%) foam for four months, with minimal side effects compared to oral finasteride. They also use a derma needler and injectable testosterone, noting no increased hair loss despite higher testosterone levels.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation discusses the fear-mongering around 5AR inhibitors like finasteride for hair loss, with some users arguing about the percentage and severity of side effects. The main point is that while some experience side effects, others believe these are reversible, and the focus should be on informed decision-making rather than spreading fear.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.